Previous 10 | Next 10 |
WAYNE, Pa., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory and dermatological diseases, today announced it will report financial results for the second quarter 2019, Thursday, August 8 th ...
NEW YORK , July 31, 2019 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Aclaris Therapeutics, Inc. ("Aclaris" or the "Company") (NASDAQ: ACRS) of the September 30, 2019 deadline to seek the role of lead plaintiff in a federal ...
2U (NASDAQ: TWOU ) -41% on Q2 earnings . More news on: 2U, Inc., Sigma Labs, Inc., T2 Biosystems, Inc., Stocks on the move, Read more ...
Aclaris Therapeutics (NASDAQ: ACRS ) says that its Phase 2 trial of ATI-501 oral in patients with Alopecia Areata met its primary endpoint . More news on: Aclaris Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ...
ATI-501 achieved statistically significant improvement over placebo in several measures of hair growth, including the primary endpoint and certain secondary endpoints of the trial. ATI-501 was generally well-tolerated at all doses. No serious adverse events or thromboembolic ...
Rigel Pharmaceuticals' ( RIGL ) Tavalisse, launched in mid-2018, is experiencing sales growth but competitors exist that could potentially reduce peak sales. RIGL's partnered pipeline provides a source of potentially good news to offset any bad news regarding advances from RIGL's competitors...
Gainers: Camber Energy (NYSEMKT: CEI ) +107% . Acacia Communications (NASDAQ: ACIA ) +35% . Electrameccanica Vehicles (NASDAQ: SOLO ) +26% . Xenetic Biosciences (NASDAQ: XBIO ) +16% . iFresh Inc. (NASDAQ: IFMK ) +15% . Atreca (NASDAQ: BCEL ) +15% . Pareteum Corporation (NASDAQ:...
The USPTO has issued Aclaris Therapeutics (NASDAQ: ACRS ), Patent No. 10,335,391 covering methods of treating facial erythema associated with rosacea using a 1.0% w/w oxymetazoline hydrochloride composition. More news on: Aclaris Therapeutics, Inc., Healthcare stocks news, Read more ...
Issuance of U.S. Patent No. 10,335,391 Further Strengthens Aclaris’ RHOFADE Patent Portfolio WAYNE, Pa., July 09, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory and dermatological dis...
WAYNE, Pa., July 03, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory and dermatological diseases, today announced the appointment of Maxine Gowen to its board of directors, effective July 2, 2019. ...
News, Short Squeeze, Breakout and More Instantly...
Aclaris Therapeutics Inc. Company Name:
ACRS Stock Symbol:
NASDAQ Market:
Aclaris Therapeutics Inc. Website:
- Non-Dilutive Transaction Strengthens Balance Sheet to Support Strategic Priorities - - $26.5 Million Upfront Plus Up to $5.0 Million Milestone - WAYNE, Pa., July 16, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company ...
WAYNE, Pa., June 06, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, Interim President & CEO of Aclaris, will part...
- Progressing ATI-2138 into Atopic Dermatitis - - Management to Host Conference Call at 5:00 PM ET Today - WAYNE, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidat...